Skip to main content
    V

    Veru Inc (VERU)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.08
    -0.01 (-0.48%)

    Market Cap: $35.64M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Veru Inc (VERU) Earnings: Report Dates and Results

    Updated Aug 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    VERU is expected to report earnings on Dec 15, 2026. In the quarter ended Jun 30, 2026, VERU reported EPS of -$0.30, above the -$0.32 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    46%(17/37)
    Avg Surprise
    -11.74%
    Streak
    4 Q

    Upcoming Estimates

    Reports Dec 15, 2026 (est.)Period ending Sep 30, 2026
    EPS Consensus-$0.31
    Range-$0.33 - -$0.27
    5 analysts
    Revenue Consensus
    N/A
    RangeN/A
    5 analysts
    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.26
    Range-$0.33 - -$0.19
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago-$0.19-36.8%
    Current-$0.26
    Revenue Consensus
    N/A
    RangeN/A
    2 analysts

    Next Report

    VERU has an expected report date of Dec 15, 2026.

    VERU Earnings Call

    The latest VERU earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, VERU beat 17, missed 18 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2018, when EPS landed 650.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.30-$0.32-$0.34 - -$0.30+6.25%BeatN/A21 up, 1 downAug 10, 2026N/A
    Mar 31, 2026-$0.13-$0.28-$0.37 - -$0.20+53.57%BeatN/A20 up, 0 downMay 13, 2026N/A
    Dec 31, 2025-$0.26-$0.47-$0.63 - -$0.31+44.68%BeatN/A20 up, 0 downFeb 11, 2026N/A
    Sep 30, 2025$0.09-$0.06N/A+258.73%BeatN/A10 up, 1 downDec 17, 2025$247064
    Jun 30, 2025-$0.53-$0.50-$0.50 - -$0.50-6.00%MissN/A20 up, 0 downAug 12, 2025N/A
    Mar 31, 2025-$0.60-$0.50-$0.50 - -$0.50-20.00%MissN/A10 up, 0 downMay 8, 2025N/A
    Dec 31, 2024-$0.71-$0.80-$0.80 - -$0.80+11.25%BeatN/A10 up, 0 downFeb 13, 2025N/A
    Sep 30, 2024-$0.05-$0.08-$0.08 - -$0.08+35.00%BeatN/A10 up, 0 downDec 16, 2024$6.66M
    Jun 30, 2024-$0.76-$0.60-$0.70 - -$0.50-26.67%MissN/A50 up, 0 downAug 8, 2024N/A
    Mar 31, 2024-$0.91-$1.50N/A+39.33%BeatN/A32 up, 0 downApr 1, 2024N/A
    Dec 31, 2023-$0.08-$0.10-$0.15 - -$0.08+20.00%BeatN/A30 up, 0 downFeb 14, 2024N/A
    Sep 30, 2023-$1.37-$2.35-$2.70 - -$2.00+41.70%BeatN/A20 up, 0 downDec 8, 2023$3.86M
    Jun 30, 2023-$1.24-$2.90-$2.90 - -$1.20+57.24%BeatN/A20 up, 0 downAug 10, 2023$3.34M
    Mar 31, 2023-$4.32-$3.30-$3.50 - -$3.10-30.91%MissN/A40 up, 0 downMay 11, 2023$6.59M
    Dec 31, 2022-$4.60-$3.77-$4.10 - -$3.40-22.02%MissN/A30 up, 0 downFeb 9, 2023$2.51M
    Sep 30, 2022-$0.51-$0.30-$0.34 - -$0.27-70.00%MissN/A50 up, 0 downDec 5, 2022$2.59M
    Jun 30, 2022-$2.80-$1.64N/A-70.73%MissN/AN/A0 up, 0 downAug 11, 2022$9.60M
    Mar 31, 2022-$1.80-$1.15-$2.60 - -$0.80-56.52%MissN/A40 up, 0 downMay 12, 2022$13.03M
    Dec 31, 2021-$0.80-$0.67-$2.30 - -$0.60-19.40%MissN/A40 up, 0 downFeb 9, 2022$14.14M
    Sep 30, 2021-$0.05-$0.09-$0.13 - -$0.06+44.44%Beat-266.7%52 up, 1 downDec 2, 2021$15.65M
    Jun 30, 2021-$0.30-$0.60-$0.80 - -$0.50+50.00%BeatN/A5N/AAug 12, 2021$17.66M
    Mar 31, 2021-$0.40-$0.30-$0.70 - -$0.20-33.33%MissN/A5N/AMay 12, 2021$13.34M
    Dec 31, 2020-$0.20-$0.40-$0.80 - -$0.20+50.00%BeatN/A3N/AFeb 10, 2021$14.62M
    Sep 30, 2020$0.03-$0.04-$0.04 - -$0.03+175.00%BeatN/A3N/ADec 9, 2020$11.75M
    Jun 30, 2020-$0.50-$0.32-$0.40 - -$0.20-56.25%MissN/A3N/AAug 13, 2020$10.32M
    Mar 31, 2020-$0.10-$0.33-$0.70 - -$0.20+69.70%BeatN/A4N/AMay 13, 2020$9.94M
    Dec 31, 2019-$0.50-$0.23-$0.50 - $0.00-117.39%MissN/A3N/AFeb 12, 2020$10.58M
    Sep 30, 2019-$0.05-$0.05-$0.06 - -$0.040.00%In lineN/A4N/ADec 12, 2019$8.73M
    Jun 30, 2019-$0.40-$0.45-$0.50 - -$0.40+11.11%BeatN/A4N/AAug 8, 2019$9.73M
    Mar 31, 2019-$0.60-$0.60-$0.80 - -$0.400.00%In lineN/A4N/AMay 15, 2019$6.98M
    Dec 31, 2018-$0.30-$0.04-$0.08 - $0.00-650.00%MissN/A2N/AFeb 13, 2019$6.37M
    Sep 30, 2018-$0.14-$0.08N/A-75.00%MissN/AN/AN/ADec 13, 2018$5.20M
    Jun 30, 2018-$1.50-$0.80-$1.10 - -$0.40-87.50%MissN/A4N/AAug 14, 2018$5.50M
    Mar 31, 2018-$0.70-$0.50-$0.80 - -$0.20-40.00%MissN/A2N/AMay 9, 2018$2.57M
    Dec 31, 2017-$0.40-$0.30-$0.30 - -$0.30-33.33%MissN/A1N/AJan 2, 2018$2.59M
    Jun 30, 2017-$0.30-$0.80N/A+62.50%Beat-1630.6%N/AN/AAug 8, 2017$4.31M
    Mar 31, 2017-$0.06-$0.04N/A-50.00%Miss-5100.0%N/AN/AMay 9, 2017$2.41M
    Dec 31, 2016-$0.04N/AN/AN/AN/A-185.8%N/AN/AFeb 9, 2017$3.24M
    Sep 30, 2016-$0.06N/AN/AN/AN/A-348.6%N/AN/ADec 12, 2016$3.56M
    Jun 30, 2016$0.02N/AN/AN/AN/A-51.8%N/AN/AJul 28, 2016$5.56M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Sep 30, 2026 was -$0.69, after -$1.75 the year before. It was $0.01 for the year ended Sep 30, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Sep 30, 2026-$0.69N/A
    Sep 30, 2025-$1.75N/A
    Sep 30, 2024-$1.80N/A
    Sep 30, 2023-$11.53N/A
    Sep 30, 2022-$5.91N/A
    Sep 30, 2021-$0.95N/A
    Sep 30, 2020-$1.07N/A
    Sep 30, 2019-$1.35N/A
    Sep 30, 2018-$3.14-26744.9%
    Sep 30, 2016$0.01N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,300 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20264,3326
    2026Q1Mar 31, 20263,4525
    2025Q4Dec 31, 20254,7316
    2025Q3Sep 30, 20256,03911
    2025Q2Jun 30, 20256,10710
    2025Q1Mar 31, 20256,1489
    2024Q2Jun 30, 20247,3369

    2026Q2 Earnings Call

    Opening remarks

    Sam Fisch Executive Director, Investor Relations and Corporate Communications The statements made on this conference call may be forward-looking statements. Forward-looking statements may include, but are not necessarily limited to, statements of the company's plans, objectives, expectations or intentions regarding its business, operations, regulatory interactions, finances and development and product portfolio. Such forward-looking statements are subject to known and unknown risks and uncertainties, and our actual results may differ significantly from those projected, suggested or included in any forward-looking statements. Risks that may cause actual results or developments to differ materially are contained in our 10-Q and 10-K SEC filings as well as in our press releases from time to time. I would now like to turn the conference call over to Dr. Mitchell Steiner, Veru Inc.'s Chairman, CEO and President.

    Mitchell Steiner Chairman, CEO and President Good morning. With me on this morning's call are Dr. Gary Barnette, the Chief Scientific Officer; Michelle Greco, the Chief Financial Officer and Chief Administrative Officer; Phil Greenberg, General Counsel; and Sam Fisch, the Executive Director of Investor Relations and Corporate Communications. Thank you for joining our second quarter fiscal year 2026 earnings call. Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two novel small molecules, enobosarm and sabizabulin. The first one, enobosarm, is an oral selective androgen receptor modulator, SARM, and is being developed as a next-generation drug that when combined with a GLP-1 receptor agonist makes weight reduction more tissue selective for fat loss and preservation of lean mass and physical function, which is intended to lead to greater weight loss compared to GLP-1 receptor agonist treatment alone, with a focus on older patients with obesity. Our second asset, sabizabulin, is a microtubule disruptor and it's being developed as a broad anti-inflammatory agent to reduce vascular plaque inflammation to slow the progression or promote the regression of atherosclerotic cardiovascular disease. This morning, we'll focus on an update of the clinical development progress of enobosarm in our obesity program. We will also provide financial highlights for fiscal 2026 second quarter ended March 31, 2026. GLP-1 receptor agonists have been shown to produce significant weight loss in patients who are overweight or have obesity. Unfortunately, this weight loss is tissue nonselective with significant indiscriminate loss of both lean mass and fat mass. Of the total weight loss, up to 50% is attributable to lean mass. Although GLP-1 receptor agonist treatments have resulted in substantial weight loss for many patients, the strategy for the next generation of obesity drugs should be a combination therapy with a GLP-1 receptor agonist to cause weight reduction while preserving lean mass and physical function and bone mineral density with the highest quality weight reduction.

    Frequently Asked Questions About VERU

    When is VERU's next earnings date?

    VERU's next earnings report is expected for Dec 15, 2026.

    Did VERU beat earnings estimates last quarter?

    Yes. VERU reported EPS of -$0.30 for the quarter ended Jun 30, 2026, above the -$0.32 estimate, a 6.25% surprise.

    What EPS do analysts expect from VERU next quarter?

    The consensus EPS estimate for VERU for the quarter ended Sep 30, 2026 is -$0.31 from 5 analysts, with estimates from -$0.33 to -$0.27.

    How often does VERU beat earnings estimates?

    VERU beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +47.94%.